[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1148689A1 - Use of aprotinin polypeptides as carriers in pharmaceutical conjugates - Google Patents

Use of aprotinin polypeptides as carriers in pharmaceutical conjugates

Info

Publication number
HK1148689A1
HK1148689A1 HK11102916.4A HK11102916A HK1148689A1 HK 1148689 A1 HK1148689 A1 HK 1148689A1 HK 11102916 A HK11102916 A HK 11102916A HK 1148689 A1 HK1148689 A1 HK 1148689A1
Authority
HK
Hong Kong
Prior art keywords
conjugates
carriers
aprotinin
drug
pharmaceutical conjugates
Prior art date
Application number
HK11102916.4A
Other languages
English (en)
Inventor
Richard Beliveau
Michel Demeule
Christian Che
Anthony Regina
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of HK1148689A1 publication Critical patent/HK1148689A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK11102916.4A 2005-07-15 2011-03-23 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates HK1148689A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69937505P 2005-07-15 2005-07-15
US75853206P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
HK1148689A1 true HK1148689A1 (en) 2011-09-16

Family

ID=37668389

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102916.4A HK1148689A1 (en) 2005-07-15 2011-03-23 Use of aprotinin polypeptides as carriers in pharmaceutical conjugates

Country Status (16)

Country Link
US (3) US8969310B2 (fr)
EP (4) EP2471555A3 (fr)
JP (3) JP5436856B2 (fr)
CN (1) CN101262890B (fr)
AU (1) AU2006272405B2 (fr)
BR (1) BRPI0613005A8 (fr)
CA (1) CA2614687C (fr)
DK (2) DK2233156T3 (fr)
ES (2) ES2424242T3 (fr)
HK (1) HK1148689A1 (fr)
HR (1) HRP20130720T1 (fr)
PL (1) PL2233156T3 (fr)
PT (1) PT2233156E (fr)
RU (2) RU2422143C2 (fr)
SI (1) SI2233156T1 (fr)
WO (1) WO2007009229A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
CA2589860A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
SI2360258T1 (sl) * 2005-02-18 2015-02-27 Angiochem Inc. Polipeptidi aprotinina za prenos spojine preko krvno-moĹľganske pregrade
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
EP2662096A1 (fr) 2005-08-24 2013-11-13 ImmunoGen, Inc. Procédé de préparation de conjugués d'anticorps de maytansinoïde
CA2666841A1 (fr) 2006-10-19 2008-04-24 Angiochem, Inc. Composes destines a stimuler le fonctionnement de la p-glycoproteine et leurs utilisations
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN101815724B (zh) * 2007-05-29 2015-02-25 安吉奥开米公司 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
DK2164866T3 (da) * 2007-05-29 2014-07-28 Angiochem Inc Aprotininlignende polypeptider til fremføring af midler, der er konjugeret dertil, til væv
US20110039785A1 (en) * 2007-12-20 2011-02-17 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
EP2235058A2 (fr) 2007-12-21 2010-10-06 Amgen, Inc Anticorps anti-amyloïde et utilisations de ceux-ci
PT2279008T (pt) * 2008-04-18 2019-05-20 Angiochem Inc Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização
AU2009304505A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010043047A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugués d'agonistes de glp-1 et leurs utilisations
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
EP2373789A4 (fr) 2008-12-17 2012-08-29 Angiochem Inc Inhibiteurs de la métalloprotéine matricielle de type 1 membranaire et leurs utilisations
DE102009006228A1 (de) 2009-01-27 2010-07-29 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen
JP2010229122A (ja) * 2009-03-06 2010-10-14 Kumamoto Univ 抗癌剤、医薬、及び癌疾患の検査薬
RU2011146654A (ru) * 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
EP2437790B1 (fr) 2009-06-03 2019-02-20 Immunogen, Inc. Procédés de conjugaison
IN2012DN00248A (fr) 2009-07-02 2015-05-01 Angiochem Inc
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
WO2012037687A1 (fr) * 2010-09-23 2012-03-29 Angiochem Inc. Polypeptides thérapeutiques et leurs utilisations
CN102085157B (zh) * 2011-01-27 2012-02-01 中国水产科学研究院黄海水产研究所 扇贝抗氧化肽纳米脂质体及其制备方法
CN102614524A (zh) * 2011-02-01 2012-08-01 复旦大学 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
SG10201702737TA (en) * 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
JP2015535523A (ja) * 2012-11-12 2015-12-14 アンジオケム インコーポレーテッド アプロチニン由来ポリペプチド−抗体コンジュゲート
CN105873598A (zh) 2013-07-03 2016-08-17 代表亚利桑那大学的亚利桑那校董会 用于治疗认知功能障碍的方法
WO2015002486A1 (fr) 2013-07-03 2015-01-08 서울대학교산학협력단 Anticorps de poulet transformé en cystéine et conjugaison spécifique de site l'utilisant
JP6666899B2 (ja) 2014-07-21 2020-03-18 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
GB201502447D0 (en) 2015-02-13 2015-04-01 Univ Liverpool Method and apparatus for sample analysis
EP3307326B9 (fr) 2015-06-15 2021-02-24 Angiochem Inc. Procédés de traitement d'une carcinomatose leptoméningée
WO2019148181A1 (fr) 2018-01-29 2019-08-01 Cognos Therapeutics, Inc. Administration intratumorale de bortézomib
CN111529716B (zh) * 2020-06-02 2021-05-28 南方医科大学 一种多肽-紫杉醇偶联物及其应用

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US508697A (en) * 1893-11-14 Jar or bottle receiver
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
ES8407536A1 (es) * 1983-10-07 1984-10-01 Jumberca Sa Mejoras en los alimentadores de hilo para telares circulares de genero de punto dotados de dispositivos listadores.
WO1987005702A1 (fr) 1986-03-13 1987-09-24 Biotechnology Australia Pty. Ltd. Procede d'analyse de l'inhibine
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5807980A (en) 1992-07-13 1998-09-15 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor VIIa-tissue factor complex
EP0599303A3 (fr) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Conjugués peptidiques
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
WO1994019692A1 (fr) * 1993-02-18 1994-09-01 The General Hospital Corporation Substance therapeutique destinee a la maladie d'alzheimer
WO1996031531A2 (fr) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Peptides fluorescent
AU5854096A (en) 1995-05-08 1996-11-29 Scios Inc. Kunitz type protease inhibitors
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
CA2222231A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
BR9708021A (pt) 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
WO1997040160A1 (fr) 1996-04-24 1997-10-30 Rijksuniversiteit Te Groningen Proteine procaryote possedant une homologie fonctionnelle et structurelle avec la glycoproteine humaine p codee par le gene mdr-1, codage de cette proteine au moyen d'acides nucleiques et cellules exprimant celle-ci
AU729643B2 (en) 1996-05-01 2001-02-08 Antivirals Inc. Polypeptide conjugates for transporting substances across cell membranes
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO1998016201A1 (fr) 1996-10-11 1998-04-23 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP4116683B2 (ja) 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 徐放性局所送達製剤
DE69838544T2 (de) * 1997-03-04 2008-07-24 Savient Pharmaceuticals, Inc. Isolierung von gewebespezifischen peptidliganden und ihre verwendung zur ausrichtung von pharmazeutika auf zielorgane
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (fr) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibiteurs de la monoxyde d'azote-synthase
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
EP1154782A4 (fr) * 1999-02-24 2002-09-25 Uab Research Foundation Derives de taxane pour therapie ciblee contre le cancer
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) * 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2307393A1 (fr) * 2000-05-01 2001-11-01 The University Of British Columbia Chimiotherapie par administration d'un ginsenoside
CA2355334A1 (fr) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Preparations pharmaceutiques et methodes visant a inhiber la croissance de tumeurs
AU2002239282A1 (en) 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002076448A1 (fr) * 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Conjugues moleculaires destines a etre utilises dans le traitement du cancer
US7045337B2 (en) 2001-04-19 2006-05-16 The Scripps Research Institute In vivo incorporation of unnatural amino acids
DE60234057D1 (de) * 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
GEP20063806B (en) * 2001-12-20 2006-04-25 Bristol Myers Squibb Co Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
ATE365213T1 (de) * 2002-02-07 2007-07-15 Yissum Res Dev Co Aminosäuresequenzen die die fähigkeit besitzen, die durchdringung durch eine biologische barriere erleichtern
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20040077540A1 (en) 2002-06-28 2004-04-22 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
ATE512674T1 (de) 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
CA2520655A1 (fr) * 2003-04-08 2004-11-04 Biotempt, B.V. Composition comprenant des fragments d'hcg pour administration par voie mucosale et buccale
CR20120384A (es) * 2003-05-14 2016-12-02 Immunogen Inc Composición de farmaco conjugado
WO2004108071A2 (fr) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Compositions et methodes destinees a cibler un polypeptide sur le systeme nerveux central
JP5624256B2 (ja) * 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1652855A4 (fr) 2003-08-08 2008-11-19 Tissue Targeting Japan Inc Polypeptides agissant sur des predispositions a des pathologies cerebrales et utilisation desdits polypeptides
EP1663278A4 (fr) * 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp Peptides mimetiques epo et proteines de fusion
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
JP2008507280A (ja) * 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
AU2005266184A1 (en) 2004-07-26 2006-02-02 Asterion Limited Linkers
EP1799826B1 (fr) 2004-09-29 2009-08-12 Children's Memorial Hospital SILENCAGE GENIQUE INDUIT PAR ARNsi DE LA SYNUCLEINE ALPHA
SI2360258T1 (sl) 2005-02-18 2015-02-27 Angiochem Inc. Polipeptidi aprotinina za prenos spojine preko krvno-moĹľganske pregrade
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
NZ560879A (en) 2005-02-18 2010-04-30 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20080030564A (ko) * 2005-05-12 2008-04-04 태피스트리 파마슈티컬스 인코퍼레이티드 표적 컨쥬게이트에 적합한 분자 구조물
WO2006138343A2 (fr) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprenant des variants de proteine associee au recepteur (rap) specifiques a lrp2, et utilisations correspondantes
DK2233156T3 (da) 2005-07-15 2013-08-05 Angiochem Inc Anvendelse af aprotininpolypeptider som bærere i farmaceutiske konjugater
BRPI0615562A2 (pt) * 2005-07-19 2010-01-26 Univ Illinois agentes de transporte para atravessamento da barreira sangue-cérebro e entrada nas células cancerìgenas do cérebro e métodos para o seu uso
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
EP1934359A2 (fr) 2005-09-08 2008-06-25 Nastech Pharmaceutical Company Inc. Compositions pharmaceutiques pour acheminer de l'acide ribonucléique dans une cellule
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
JP2009513716A (ja) 2005-11-01 2009-04-02 アルナイラム ファーマシューティカルズ インコーポレイテッド ＲＮＡｉによるインフルエンザウイルス複製の抑制
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CA2658654A1 (fr) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Proteines de fusion d'extendine
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
CA2666841A1 (fr) 2006-10-19 2008-04-24 Angiochem, Inc. Composes destines a stimuler le fonctionnement de la p-glycoproteine et leurs utilisations
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN101815724B (zh) 2007-05-29 2015-02-25 安吉奥开米公司 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
US8802631B2 (en) 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (fr) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Protéines de fusion assurant le transport du gdnf jusqu'au système nerveux central
US20110039785A1 (en) 2007-12-20 2011-02-17 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
ES2951646T3 (es) 2008-02-21 2023-10-24 Burnham Institute For Medical Res Métodos y composiciones relacionados con péptidos y proteínas con elementos C-terminales
PT2279008T (pt) 2008-04-18 2019-05-20 Angiochem Inc Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização
AU2009304505A1 (en) * 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010043047A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugués d'agonistes de glp-1 et leurs utilisations
MX2011005965A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de leptina y de análogos de leptina y sus usos de los mismos.
WO2010063124A1 (fr) 2008-12-05 2010-06-10 Angiochem Inc. Conjugués thérapeutiques peptidiques et leurs applications
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
EP2373789A4 (fr) 2008-12-17 2012-08-29 Angiochem Inc Inhibiteurs de la métalloprotéine matricielle de type 1 membranaire et leurs utilisations
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
US20100284921A1 (en) 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
CN103819564A (zh) 2009-06-11 2014-05-28 安吉奥开米公司 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
IN2012DN00248A (fr) 2009-07-02 2015-05-01 Angiochem Inc
SI2453923T1 (sl) 2009-07-14 2016-04-29 Mayo Foundation For Medical Education And Research S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
US20120277158A1 (en) 2009-10-06 2012-11-01 Angiochem Inc. Compositions and methods for the transport of therapeutic agents
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
WO2011153642A1 (fr) 2010-06-10 2011-12-15 Angiochem Inc. Conjugués et protéines de fusion de la leptine et d'analogues de la leptine et leur utilisation
JP2013530993A (ja) 2010-07-02 2013-08-01 アンジオケム インコーポレーテッド 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用
WO2012037687A1 (fr) 2010-09-23 2012-03-29 Angiochem Inc. Polypeptides thérapeutiques et leurs utilisations
CN103561726A (zh) 2010-11-18 2014-02-05 通用医疗公司 用于癌症治疗的抗高血压剂的新型组合物和用途
WO2013056096A1 (fr) 2011-10-13 2013-04-18 Angiochem Inc. Conjugués polypeptides opioïdes et utilisations associées
CN104136606A (zh) 2011-12-01 2014-11-05 安吉奥开米公司 靶向的艾杜糖-2-硫酸酯酶化合物
BR112014013161A2 (pt) 2011-12-01 2019-09-24 Angiochem Inc compostos com enzima lisossomal alvo
US20150147310A1 (en) 2012-06-15 2015-05-28 Angiochem Inc. Targeted enzyme compounds and uses thereof
CN104781281A (zh) 2012-08-14 2015-07-15 安吉奥开米公司 包含抗体部分、穿过血脑屏障的多肽和细胞毒素的结合物
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
JP2015535523A (ja) 2012-11-12 2015-12-14 アンジオケム インコーポレーテッド アプロチニン由来ポリペプチド−抗体コンジュゲート
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
WO2014082184A1 (fr) 2012-11-30 2014-06-05 Angiochem Inc. Composés d'iduronate-2-sulfatase ciblés
HK1179821A2 (en) 2013-05-28 2013-10-04 Chit Shun Catv Equipment Ltd High voltage discharge protection device and radio frequency transmission apparatus using the same
WO2014194428A1 (fr) 2013-06-06 2014-12-11 Angiochem Inc. Composés d'héparane sulfatase ciblés
US20160367691A1 (en) 2013-06-06 2016-12-22 Angiochem Inc. Targeted enzyme compounds and uses thereof

Also Published As

Publication number Publication date
RU2008105677A (ru) 2009-08-20
SI2233156T1 (sl) 2013-09-30
JP2009500431A (ja) 2009-01-08
RU2011115418A (ru) 2012-10-27
US8969310B2 (en) 2015-03-03
HRP20130720T1 (en) 2013-09-30
PL2233156T3 (pl) 2013-09-30
PT2233156E (pt) 2013-07-31
EP2471555A2 (fr) 2012-07-04
DK2233156T3 (da) 2013-08-05
RU2422143C2 (ru) 2011-06-27
DK2433653T3 (da) 2019-08-19
EP1907009A1 (fr) 2008-04-09
AU2006272405A1 (en) 2007-01-25
ES2424242T3 (es) 2013-09-30
CA2614687C (fr) 2016-03-22
JP5436856B2 (ja) 2014-03-05
EP1907009A4 (fr) 2009-09-02
EP2471555A3 (fr) 2012-10-17
ES2744225T3 (es) 2020-02-24
EP2233156B1 (fr) 2013-05-01
US20180221497A1 (en) 2018-08-09
US20090082277A1 (en) 2009-03-26
CA2614687A1 (fr) 2007-01-25
EP2233156A2 (fr) 2010-09-29
US9713646B2 (en) 2017-07-25
EP2433653B1 (fr) 2019-06-05
BRPI0613005A8 (pt) 2017-12-26
JP2013047249A (ja) 2013-03-07
CN101262890A (zh) 2008-09-10
AU2006272405B2 (en) 2013-02-07
CN101262890B (zh) 2015-08-26
JP2015163641A (ja) 2015-09-10
BRPI0613005A2 (pt) 2010-12-14
US20150314010A1 (en) 2015-11-05
EP2433653A1 (fr) 2012-03-28
EP2233156A3 (fr) 2010-10-13
WO2007009229A1 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
HK1148689A1 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
IL179714A (en) Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation
TWI315203B (en) Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
ATE412387T1 (de) Medizinische vorrichtungen
UA105210C2 (ru) Противораковая вакцина и ее применение
IL164135A (en) 4-anilino quinazoline derivatives as antiproliferative agents, process for their preparation, pharmaceutical compositions containing such derivatives and use thereof for the preparation of medicaments for the treatment of cancer
DE60103453D1 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
IL186303A (en) 1h - benzamideimzole - 4 carboxyamides converted with quarterly carbon in position 2, the pharmaceutical composition containing it and its use for the preparation of a drug @ for the treatment @ of cancer
PT1401841E (pt) Derivados substituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno como medicamentos para o tratamento da dor
AU2682401A (en) Flavonoid drug and dosage form, its production and use
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
ITMI20021726A1 (it) Macrolidi ad attivita' antiinfiammatoria.
HK1064589A1 (en) Cancer vaccine containing cancer antigen based on tumor suppessor gene wti product and cationic liposomes
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
IL205290A (en) A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
ZA200208761B (en) Pharmaceutical form of administration for peptides, methods for its production and use.
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
AU2003287392A8 (en) Guided capsule for wireless endoscopy, biopsy, and drug delivery
ATE349221T1 (de) Extrakt mit antitumoraler und antitoxischer wirkung
WO2003018535A3 (fr) Nouvelles aminobenzophenones
EP1439199A4 (fr) Polymeres medicaux et leur utilisation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220716